Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acid-Blocking Medication in Infants With Laryngomalacia
NCT02700087Withdrawn
- Sponsor
- Stanford University
- Start
- Feb 2016
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of ranitidine and famotidine in laryngomalacia (LM) and gastroesophageal reflux disease (GERD) (2 arms), sponsored by Stanford University. Primary endpoint: Time to normalization of airway symptoms score at 10 months. Planned start Feb 2016; status: withdrawn.
02
Drugs
ranitidinefamotidine
03
Conditions
laryngomalacia (LM)gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT02700087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02700087.